NYSE:ANVS Annovis Bio (ANVS) Stock Price, News & Analysis $1.56 -0.05 (-3.11%) Closing price 05/5/2025 03:59 PM EasternExtended Trading$1.56 -0.01 (-0.32%) As of 05/5/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Annovis Bio Stock (NYSE:ANVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Annovis Bio alerts:Sign Up Key Stats Today's Range$1.54▼$1.6850-Day Range$1.21▼$1.9652-Week Range$1.11▼$17.88Volume174,515 shsAverage Volume729,177 shsMarket Capitalization$22.21 millionP/E RatioN/ADividend YieldN/APrice Target$40.67Consensus RatingBuy Company OverviewAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Read More… Annovis Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreANVS MarketRank™: Annovis Bio scored higher than 42% of companies evaluated by MarketBeat, and ranked 808th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAnnovis Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAnnovis Bio has only been the subject of 1 research reports in the past 90 days.Read more about Annovis Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Annovis Bio are expected to grow in the coming year, from ($2.19) to ($1.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annovis Bio is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annovis Bio is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Annovis Bio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted18.05% of the float of Annovis Bio has been sold short.Short Interest Ratio / Days to CoverAnnovis Bio has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Annovis Bio has recently decreased by 13.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnnovis Bio does not currently pay a dividend.Dividend GrowthAnnovis Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.05% of the float of Annovis Bio has been sold short.Short Interest Ratio / Days to CoverAnnovis Bio has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Annovis Bio has recently decreased by 13.86%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Annovis Bio this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ANVS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Annovis Bio insiders have not sold or bought any company stock.Percentage Held by Insiders32.30% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.83% of the stock of Annovis Bio is held by institutions.Read more about Annovis Bio's insider trading history. Receive ANVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ANVS Stock News HeadlinesAnnovis Bio hires new director of biostatistics amid AD trialMay 1, 2025 | uk.investing.comAnnovis Bio stellt neuen Direktor für BiostatistikApril 29, 2025 | de.investing.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 6, 2025 | Golden Portfolio (Ad)Annovis Bio Appoints Hui Liu as Director of BiostatisticsApril 29, 2025 | globenewswire.comAnnovis Bio-Aktie stürzt auf 52-Wochen-Tief von 1,14 US-DollarApril 10, 2025 | de.investing.comAnnovis Bio Receives Non-Compliance Notice from NYSEMarch 29, 2025 | msn.comAnnovis Bio Inc.: Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSEMarch 29, 2025 | finanznachrichten.deAnnovis Bio receives noncompliance notification from NYSEMarch 28, 2025 | markets.businessinsider.comSee More Headlines ANVS Stock Analysis - Frequently Asked Questions How have ANVS shares performed this year? Annovis Bio's stock was trading at $5.03 at the start of the year. Since then, ANVS stock has decreased by 69.0% and is now trading at $1.56. View the best growth stocks for 2025 here. How were Annovis Bio's earnings last quarter? Annovis Bio, Inc. (NYSE:ANVS) released its quarterly earnings results on Friday, March, 21st. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.05. When did Annovis Bio IPO? Annovis Bio (ANVS) raised $10 million in an initial public offering (IPO) on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) served as the underwriter for the IPO. Who are Annovis Bio's major shareholders? Top institutional shareholders of Annovis Bio include Lokken Investment Group LLC (0.21%). View institutional ownership trends. How do I buy shares of Annovis Bio? Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Annovis Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annovis Bio investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings3/21/2025Today5/05/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ANVS CIK1477845 Webwww.annovisbio.com Phone610-727-3913FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$40.67 High Stock Price Target$67.00 Low Stock Price Target$25.00 Potential Upside/Downside+2,506.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,200,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-311.00% Debt Debt-to-Equity RatioN/A Current Ratio2.66 Quick Ratio2.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.73) per share Price / Book-2.14Miscellaneous Outstanding Shares14,236,000Free Float9,638,000Market Cap$22.21 million OptionableOptionable Beta1.46 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NYSE:ANVS) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.